TMCnet News

Japan HER2-Positive Breast Cancer Drug Forecast and Market Analysis to 2023 - Herceptin is the Market Leader, Taking 92% of the Market in 2013
[October 20, 2014]

Japan HER2-Positive Breast Cancer Drug Forecast and Market Analysis to 2023 - Herceptin is the Market Leader, Taking 92% of the Market in 2013


(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/8nmzxh/pharmapoint) has announced the addition of the "PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023" report to their offering.



HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

In 2013, Herceptin was the market leader, taking 92% of the Japanese market. This is due to the fact that it is the most established agent in this disease and is used in all settings, although over half of all Herceptin use is in the adjuvant setting.


Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Basic Breast Anatomy - Breast Cancer Staging - Prognosis - Quality of Life - Symptoms 4 Disease Management - Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) - Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) - Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 5 Competitive Assessment Product Profiles - HER2-Targeted Therapies - Herceptin (trastuzumab) - Tykerb (lapatinib) - Perjeta (pertuzumab) - Kadcyla (ado-trastuzumab emtansine, T-DM1) Product Profiles - General Targeted Therapies - Afinitor (everolimus) - Xeloda (capecitabine) - Avastin (bevacizumab) - Halaven (eribulin mesylate) - Abraxane (nab-paclitaxel) Hormonal Agents - Tamoxifen - Faslodex (fulvestrant) - Aromatase Inhibitors 6 Unmet Need and Opportunity - Brain Metastases - Resistance to HER2-Targeting Therapies 7 Pipeline Assessment Promising Drugs in Clinical Development - Gilotrif (afatinib) - Neratinib Promising Drugs in Early-Stage Development - Palbociclib - NeuVax (nelipepimut-S) - Patritumab - Ganetespib - ARRY-380 (ONT-380) - NVP-BYL719 Biosimilars 8 Market Outlook - Forecast - Key Events - Drivers and Barriers 9 Appendix For more information visit http://www.researchandmarkets.com/research/8nmzxh/pharmapoint CONTACT: Research and Markets, Laura Wood, Senior Manager.

[email protected] Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Breast Cancer (http://www.researchandmarkets.com/categories.asp?cat_id=207&campaign_id=8nmzxh) .

(c) 2014 M2 COMMUNICATIONS

[ Back To TMCnet.com's Homepage ]